Mainz Biomed B.V. (MYNZ) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Medical - Diagnostics & Research industria. La empresa tiene su sede en Mainz, Germany. El CEO actual es Guido Baechler.
MYNZ tiene fecha de IPO 2021-11-05, 19 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $2.86M.
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
